Trade Mark Journal No.2026/019 8 May 2026

WO0000001914246 (5,10,44)

Office of origin: Denmark

Date of International Registration:18 March 2026
Date of designation in the UK: 18 March 2026
Image for mark 1914246 CHIRLOYO

International priority date claimed: 19 September 2025 (Denmark)
Class 5
Pharmaceutical preparations, namely for treatment or prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, such as short bowel syndrome (SBS); medical preparations, namely for treatment or prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, such as short bowel syndrome (SBS); pharmaceutical preparations, namely for treatment of human patients suffering from CHI (congenital hyperinsulinism) and/or hypoglycemia; medical preparations for the treatment of human patients suffering from CHI (congenital hyperinsulinism) and/or hypoglycemia.
Class 10
Devices for introducing pharmaceutical preparations, namely for treatment and prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, such as short bowel syndrome (SBS), and parts and fittings therefor; devices for introducing pharmaceutical preparations, namely for treatment of human patients suffering from CHI (congenital hyperinsulinism) and/or hypoglycemia, and parts and fittings therefor.
Class 44
Medical and pharmaceutical services, namely in relation to treatment or prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, such as short bowel syndrome (SBS); medical and pharmaceutical advice, namely in relation to treatment or prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, such as short bowel syndrome (SBS); medical and pharmaceutical services, namely in relation to treatment of human patients suffering from CHI (congenital hyperinsulinism) and/or hypoglycemia; medical and pharmaceutical advice, namely in relation to treatment of human patients suffering from CHI (congenital hyperinsulinism) and/or hypoglycemia.

ZEALAND PHARMA A/S

Representative: PATRADE A/S, Ceresbyen 75, DK-8000 Aarhus C, DENMARK